26 Apr '24
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
PRINCETON, N.J. , April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the...
14 Mar '24
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024   CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year CytoSorb core sales...
06 Mar '24
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
PRINCETON, N.J. , March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at...
08 Feb '24
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
PRINCETON, N.J. , Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan , Chief Executive Officer, will present at...